{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:36:28Z","timestamp":1787160988199,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703332"],"award-info":[{"award-number":["81703332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002888","name":"Beijing Municipal Commission of Education","doi-asserted-by":"publisher","award":["KM201810025010"],"award-info":[{"award-number":["KM201810025010"]}],"id":[{"id":"10.13039\/501100002888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003213","name":"Beijing Municipal Education Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003213","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2018ZX097201003"],"award-info":[{"award-number":["2018ZX097201003"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.biopha.2024.117264","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T21:22:17Z","timestamp":1723584137000},"page":"117264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["PTX-RPPR, a conjugate of paclitaxel and NRP-1 peptide inhibitor to prevent tumor growth and metastasis"],"prefix":"10.1016","volume":"178","author":[{"given":"Yuanyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2159-2730","authenticated-orcid":false,"given":"Yaonan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117264_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2024.117264_bib2","first-page":"524","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2024.117264_bib3","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.21.02006","article-title":"Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (EA2108)","volume":"40","author":"Khan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.117264_bib4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2021.06.024","article-title":"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2024.117264_bib5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2024.117264_bib6","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer","volume":"383","author":"Burstein","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2024.117264_bib7","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/ja00738a045","article-title":"Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia","volume":"93","author":"Wani","year":"1971","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2024.117264_bib8","first-page":"31","article-title":"A new parenteral vehicle for the administration of some poorly soluble anti-cancer drugs","volume":"41","author":"Tarr","year":"1987","journal-title":"J. Parent. Sci. Technol."},{"key":"10.1016\/j.biopha.2024.117264_bib9","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1021\/jm00107a042","article-title":"Biologically active taxol analogues with deleted A-ring side chain substituent and variable","volume":"34","author":"Swindell","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2024.117264_bib10","first-page":"141","article-title":"Taxol: a history of pharmaceutical development and current pharmaceutical concerns","volume":"15","author":"Adams","year":"1993","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"4","key":"10.1016\/j.biopha.2024.117264_bib11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jnci\/90.4.300","article-title":"Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study","volume":"90","author":"Szebeni","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.biopha.2024.117264_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1242\/dev.103028","article-title":"Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis","volume":"141","author":"Fantin","year":"2014","journal-title":"Development"},{"key":"10.1016\/j.biopha.2024.117264_bib13","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1074\/jbc.M410924200","article-title":"Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2","volume":"280","author":"West","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.biopha.2024.117264_bib14","first-page":"272","article-title":"Neuropilin-1 is a placenta growth factor-2 receptor","volume":"273","author":"Migdal","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.117264_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0959-4388(98)80085-8","article-title":"Receptors for collapsin\/semaphorins","volume":"8","author":"Fujisawa","year":"1998","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.biopha.2024.117264_bib16","article-title":"Bioinformatics analysis and clinical significance of NRP-1 in triple-negative breast cancer","volume":"10","author":"Ma","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.biopha.2024.117264_bib17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.7150\/ijbs.86085","article-title":"VEGFA\/NRP-1\/GAPVD1 axis promotes progression and cancer stemness of triple-negative breast cancer by enhancing tumor cell-macrophage crosstalk","volume":"20","author":"Wang","year":"2024","journal-title":"Int. J. Biol."},{"key":"10.1016\/j.biopha.2024.117264_bib18","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1073\/pnas.0908201106","article-title":"C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration","volume":"106","author":"Teesalu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2024.117264_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jsb.2013.02.006","article-title":"Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor","volume":"182","author":"David Zanuy","year":"2013","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.biopha.2024.117264_bib20","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1039\/C5TB01930C","article-title":"Tetrahydro-b-carboline-3-carboxyl-thymopentin: a nano-conjugate for releasing pharmacophores to treat tumor and complications","volume":"4","author":"Hu","year":"2016","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.biopha.2024.117264_bib21","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.2147\/IJN.S212978","article-title":"RGDV-modified gemcitabine: a nano-medicine capable of prolong half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine","volume":"14","author":"Liu","year":"2019","journal-title":"Int. J. Nanomed."},{"issue":"8","key":"10.1016\/j.biopha.2024.117264_bib22","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1021\/jm101577z","article-title":"Conjugate (MTC-220) of muramyl dipeptide analogue and paclitaxel prevents both tumor growth and metastasis in mice","volume":"54","author":"Ma","year":"2011","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2024.117264_bib23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/acs.jmedchem.7b01407","article-title":"Salutaxel, a conjugate of docetaxel and a muramyl dipeptide (MDP) analogue, acts as multifunctional prodrug that inhibits tumor growth and metastasis","volume":"61","author":"Wen","year":"2018","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.biopha.2024.117264_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002275","article-title":"Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape","volume":"21","author":"Ganesan","year":"2023","journal-title":"PLOS Biol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117264_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11705-015-1538-y","article-title":"Cationic and amphipathic cell-penetrating peptides (CPPs): Their structures and in vivo studies in drug delivery","volume":"9","author":"Zaro","year":"2015","journal-title":"Front. Chem. Sci. Eng."},{"key":"10.1016\/j.biopha.2024.117264_bib26","first-page":"31","article-title":"A new parenteral vehicle for the administration of some poorly soluble anti-cancer drugs","volume":"41","author":"Tarr","year":"1987","journal-title":"J. Parent. Sci. Technol."},{"key":"10.1016\/j.biopha.2024.117264_bib27","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1021\/jm00107a042","article-title":"Biologically active taxol analogues with deleted A-ring side chain substituent and variable C-2\u2019 configurations","volume":"34","author":"Swindell","year":"1991","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2024.117264_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1570-0232(02)00913-3","article-title":"Measurement of paclitaxel in biological matrices: high-throughput liquid chromatographic-tandem mass spectrometric quantification of paclitaxel and metabolites in human and dog plasma","volume":"785","author":"Alexander","year":"2003","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.biopha.2024.117264_bib29","first-page":"35","article-title":"The search for plant sources of anticancer drugs","volume":"20","author":"Perdue","year":"1969","journal-title":"Morris Arbor. Bull."},{"key":"10.1016\/j.biopha.2024.117264_bib30","first-page":"753","article-title":"Camptothecin and Taxol: discovery to clinic-13th Bruce-F-Cain-Memorial-Award-Lecture","volume":"55","author":"Wall","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.117264_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/01459740214074","article-title":"From taxol to Taxol: the changing identities and ownership of an anti-cancer drug","volume":"21","author":"Walsh","year":"2002","journal-title":"Med Anthr."},{"key":"10.1016\/j.biopha.2024.117264_bib32","first-page":"52","article-title":"Taxol\u2019s journey from discovery to use: lessons and updates","volume":"25","author":"Tuma","year":"2003","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.biopha.2024.117264_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0168-3659(02)00320-6","article-title":"A novel controlled release formulation for the anticancer drug paclitaxel (Taxol\u00ae): PLGA nanoparticles containing vitamin E TPGS","volume":"86","author":"MU","year":"2003","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.biopha.2024.117264_bib34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","article-title":"Challenges in Development of Nanoparticle-Based Therapeutics","volume":"14","author":"DESAI","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2024.117264_bib35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.fct.2012.11.004","article-title":"Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts","volume":"52","author":"YE","year":"2013","journal-title":"Food Chem. Toxicol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117264_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00280-014-2498-5","article-title":"A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer","volume":"74","author":"AHN","year":"2014","journal-title":"Cancer Chemoth Pharm."},{"key":"10.1016\/j.biopha.2024.117264_bib37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addr.2017.02.003","article-title":"The battle of \u201cnano\u201d paclitaxel","volume":"122","author":"SOFIAS","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2024.117264_bib38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijpharm.2017.05.016","article-title":"Paclitaxel: what has been done and the challenges remain ahead","volume":"526","author":"Bernabeu","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2024.117264_bib39","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from taxol","volume":"8","author":"Weiss","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.117264_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.133.2.275","article-title":"Isolation of a tumor factor responsible for angiogenesis","volume":"133","author":"Folkman","year":"1971","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.biopha.2024.117264_bib41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bjc.6604929","article-title":"Why are tumour blood vessels abnormal and why is it important to know?","volume":"100","author":"Nagy","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2024.117264_bib42","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ajpath.2011.11.035","article-title":"Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors","volume":"180","author":"Ohga","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2024.117264_bib43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.1.5800.597","article-title":"Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action","volume":"1","author":"Le Serve","year":"1972","journal-title":"Br. Med. J."},{"key":"10.1016\/j.biopha.2024.117264_bib44","doi-asserted-by":"crossref","unstructured":"Michael McCarthy, Antiangiogenesis drug promising for metastatic colorectal cancer, The Lancet 361(9373)(2003) 1959, doi:10.1016\/S0140-6736(03)13603-3.","DOI":"10.1016\/S0140-6736(03)13603-3"},{"key":"10.1016\/j.biopha.2024.117264_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2006.10.018","article-title":"Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth","volume":"11","author":"Pan","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2024.117264_bib46","first-page":"1303","article-title":"Taxol dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer","volume":"56","author":"Lee","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2024.117264_bib47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2362.2008.02070.x","article-title":"Roleof, TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells","volume":"39","author":"Wang","year":"2009","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.biopha.2024.117264_bib48","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1038\/onc.2009.289","article-title":"TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer","volume":"28","author":"Szajnik","year":"2009","journal-title":"Oncogene"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222401148X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222401148X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:53:44Z","timestamp":1777863224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222401148X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":48,"alternative-id":["S075333222401148X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117264","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PTX-RPPR, a conjugate of paclitaxel and NRP-1 peptide inhibitor to prevent tumor growth and metastasis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117264"}}